Kids enrolled in Program Abrazos from Algarrobo, Magdalena State.

Factor-H tiene como prioridad compartir información sobre la investigación clínica de una manera responsable, sin generar expectativas irreales ni aumentar la carga emocional de las familias afectadas por la enfermedad de Huntington. El estudio Falcon-HD está evaluando SKY-0515, un fármaco experimental de administración oral desarrollado por Skyhawk Therapeutics para modular…

A central priority for Factor-H is ensuring that information about clinical research is shared in a way that does not create unrealistic expectations or add to the emotional burden faced by individuals and families affected by Huntington’s disease. While scientific progress is essential and provides reasons for optimism, it is…

On January 3rd, 2026, at 7 am (UK time), my “Hermanito” Gindel rang me. ‘They’re bombing Caracas’ he said, ‘don’t worry, I love you, I’m safe’, ‘I’ll call you later’. A call like that leaves you in a state of anxiety. Fear of the unknown. And I’m not living there.…

Dr. Ignacio Muñoz-Sanjuan, Factor-H president, shares in this article his first insights on the Skyhawk’s Therapeutics announcement from January 28. There are always two sides with any important development regarding possible treatments for a devastating condition like Huntington’s Disease: one is the scientific part of it; the other is how…

From top to bottom, the reality of neurological care for people with Huntington’s Disease in Venezuela and the delivery of therapeutic advancement A story by Alex Fisher “……as the heat is turned up on HD science and the current US administration have also turned up the heat in the region,…

Explanation in Spanish of the meaning of UniQure’s new AMT-130 therapy, with clarifications on the what and the when, by Dr. Ignacio Muñoz-Sanjuán (based on the most recent study published on September 24, 2025)

On July 10, 2024, I wrote a reflection piece following the investor conference where uniQure presented the encouraging 24-month results of AMT-130, the first HTT-directed gene therapy delivered directly into the brain regions most severely affected by mutant huntingtin —the caudate and putamen. At that time, early evidence suggested the…

Gratitude Day took place on March 23rd, 2025 and culminated a week of events in Venezuela to honor the contributions of the Venezuelan families to the advancement of science and medicine. Factor-H, working alongside Habitat LUZ, volunteers from the community and health professionals, hosted a series of events ranging from…

The December issue of the Moving Along magazine of the Movement Disorder Society published a reflection article about the scientific and humanitarian trajectory of Factor-H founder, Ignacio Muñoz-Sanjuan. The article was written in response to the Public Service Award given to Ignacio in September 2024, for the work Factor-H has…